Humanin has a remarkable origin story. It was discovered in 2001 by Japanese researchers conducting a cDNA library screen — they were looking for peptides expressed in the neurons of a deceased Alzheimer's patient that had somehow survived the disease process. The neurons that were still alive expressed a previously unknown peptide. They named it Humanin.
What made this discovery significant was not just what it was, but where it came from. Humanin is encoded by the 16S ribosomal RNA region of mitochondrial DNA — making it the first peptide known to be encoded by mitochondrial DNA with biological activity outside the mitochondria itself. This challenged the prevailing view that the mitochondrial genome was a simple, limited system encoding only 13 proteins for energy production.
Humanin is conserved across many species, found in blood and tissues, and its levels decline with age across multiple organisms. The naked mole-rat — one of nature's most remarkable longevity outliers — maintains unusually stable humanin levels throughout its lifespan. Children of human centenarians have significantly higher circulating humanin levels than age-matched controls. These observations don't prove causation, but they form a compelling pattern.
Unlike MOTS-c (which primarily influences metabolism via AMPK) or SS-31 (which stabilises mitochondrial structure), Humanin's primary role is cytoprotection — preventing cell death, particularly in neurons and other high-energy tissues. It achieves this through several converging mechanisms.
A key distinction from MOTS-c: Humanin has identified cell-surface receptors, which gives researchers more tools to study its pharmacology and develop analogues. The potent analogue HNG (where serine 14 is replaced by glycine) shows significantly stronger activity than native Humanin and is used in most animal longevity studies. Much of what the community discusses as "humanin" research actually used HNG.
Humanin occupies a more niche position in the biohacking community than MOTS-c or the recovery peptides. It is less frequently discussed, harder to source, and the use cases are less immediately tangible — neuroprotection and longevity are harder to feel subjectively than muscle recovery or energy levels. Those who do experiment with it tend to be deeply engaged with the longevity science and often use it as part of broader mitochondrial protocols.
Community dosing is largely extrapolated from animal studies. Native humanin doses in mouse studies range widely. Some practitioners advocate for the HNG analogue over native humanin due to its stronger potency, though availability of pharmaceutical-grade HNG is even more limited. The community generally treats humanin as a long-term, low-frequency protocol rather than a loading/maintenance approach.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
Humanin has one of the most compelling origin stories and longevity correlations of any peptide in this book — found in surviving Alzheimer's neurons, higher in centenarian children, stable in the world's longest-lived rodent. The neuroprotective mechanism is well-characterised, the Alzheimer's animal data is consistent, and there is genuine human genetic evidence linking humanin levels to cognitive ageing.
The gap between that compelling picture and validated therapeutic use is, however, very wide. No human being has been given exogenous humanin in a published clinical trial. The longevity correlations, however striking, are observational. Most of the quantitative animal research used the HNG analogue, not native humanin. Community-available humanin comes from grey-market sources with no quality verification.
Of the three mitochondrial-derived peptides covered in Part Three (alongside SS-31 and MOTS-c), humanin has the most intriguing longevity biology — and the least actionable human evidence. It is a peptide to watch closely as clinical research develops, rather than to use confidently now.